Sean P Gaine

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5239567/publications.pdf

Version: 2024-02-01

99 papers	18,488 citations	57631 44 h-index	40881 93 g-index
105 all docs	105 docs citations	105 times ranked	12151 citing authors

#	Article	IF	Citations
1	Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). European Heart Journal, 2009, 30, 2493-2537.	1.0	3,108
2	2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). European Heart Journal, 2020, 41, 543-603.	1.0	2,426
3	Updated Clinical Classification of Pulmonary Hypertension. Journal of the American College of Cardiology, 2009, 54, S43-S54.	1.2	1,919
4	Guidelines for the diagnosis and treatment of pulmonary hypertension. European Respiratory Journal, 2009, 34, 1219-1263.	3.1	1,127
5	Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease. Annals of Internal Medicine, 2000, 132, 425.	2.0	905
6	Chronic Thromboembolic Pulmonary Hypertension (CTEPH). Circulation, 2011, 124, 1973-1981.	1.6	860
7	Diagnosis and differential assessment of pulmonary arterial hypertension. Journal of the American College of Cardiology, 2004, 43, S40-S47.	1.2	819
8	Selexipag for the Treatment of Pulmonary Arterial Hypertension. New England Journal of Medicine, 2015, 373, 2522-2533.	13.9	790
9	Long-Term Outcome of Patients With Chronic Thromboembolic Pulmonary Hypertension. Circulation, 2016, 133, 859-871.	1.6	506
10	Primary pulmonary hypertension. Lancet, The, 1998, 352, 719-725.	6.3	505
11	Changing Demographics, Epidemiology, and Survival of Incident Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 790-796.	2.5	483
12	Pulmonary hypertension in chronic lung disease and hypoxia. European Respiratory Journal, 2019, 53, 1801914.	3.1	428
13	Dysfunctional Voltage-Gated K ⁺ Channels in Pulmonary Artery Smooth Muscle Cells of Patients With Primary Pulmonary Hypertension. Circulation, 1998, 98, 1400-1406.	1.6	385
14	Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: Results from the COMPERA registry. International Journal of Cardiology, 2013, 168, 871-880.	0.8	357
15	Dynamic Risk Stratification of Patient Long-Term Outcome After Pulmonary Endarterectomy. Circulation, 2016, 133, 1761-1771.	1.6	307
16	Attenuated K+ channel gene transcription in primary pulmonary hypertension. Lancet, The, 1998, 351, 726-727.	6.3	263
17	Efficacy and Safety of Treprostinil: An Epoprostenol Analog for Primary Pulmonary Hypertension. Journal of Cardiovascular Pharmacology, 2003, 41, 293-299.	0.8	219
18	End Points and Clinical Trial Design in Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2009, 54, S97-S107.	1.2	209

#	Article	IF	Citations
19	Pulmonary Hypertension. JAMA - Journal of the American Medical Association, 2000, 284, 3160.	3.8	137
20	emPHasis-10: development of a health-related quality of life measure in pulmonary hypertension. European Respiratory Journal, 2014, 43, 1106-1113.	3.1	131
21	PORTOPULMONARY HYPERTENSION AND THE LIVER TRANSPLANT CANDIDATE. Transplantation, 1999, 67, 1087-1093.	0.5	122
22	SUCCESSFUL USE OF CHRONIC EPOPROSTENOL AS A BRIDGE TO LIVER TRANSPLANTATION IN SEVERE PORTOPULMONARY HYPERTENSION1. Transplantation, 1998, 65, 457-459.	0.5	115
23	ERS statement on exercise training and rehabilitation in patients with severe chronic pulmonary hypertension. European Respiratory Journal, 2019, 53, 1800332.	3.1	110
24	Epoprostenol for Treatment of Pulmonary Hypertension in Patients With Systemic Lupus Erythematosus. Chest, 2000, 117, 14-18.	0.4	109
25	COVID-19 induces a hyperactive phenotype in circulating platelets. PLoS Biology, 2021, 19, e3001109.	2.6	108
26	Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension. European Respiratory Journal, 2017, 50, 1602493.	3.1	97
27	Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality. Journal of the American College of Cardiology, 2018, 71, 752-763.	1.2	82
28	Temporal trends and drug exposures in pulmonary hypertension: An American experience. American Heart Journal, 2006, 152, 521-526.	1.2	78
29	Lung-selective gene responses to alveolar hypoxia: potential role for the bone morphogenetic antagonist gremlin in pulmonary hypertension. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2008, 295, L272-L284.	1.3	78
30	Recent advances in targeting the prostacyclin pathway in pulmonary arterial hypertension. European Respiratory Review, 2015, 24, 630-641.	3.0	78
31	Survival in portopulmonary hypertension: Outcomes of the United Kingdom National Pulmonary Arterial Hypertension Registry. Journal of Heart and Lung Transplantation, 2017, 36, 770-779.	0.3	73
32	Liver transplantation in patients with severe portopulmonary hypertension treated with preoperative chronic intravenous epoprostenol. Liver Transplantation, 2001, 7, 745-749.	1.3	70
33	Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study. American Journal of Cardiovascular Drugs, 2018, 18, 37-47.	1.0	69
34	Clinical trial protocol for TRANSFORMâ€UK: A therapeutic openâ€label study of tocilizumab in the treatment of pulmonary arterial hypertension. Pulmonary Circulation, 2018, 8, 1-8.	0.8	67
35	Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension. Circulation, 2019, 139, 2440-2450.	1.6	67
36	Role of Gremlin in the Lung. American Journal of Respiratory Cell and Molecular Biology, 2010, 42, 517-523.	1.4	63

#	Article	IF	Citations
37	Corrigendum to: 'Guidelines for the diagnosis and treatment of pulmonary hypertension' [European Heart Journal (2009) 30, 2493-2537]. The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). European Heart Journal, 2011, 32, 926-926.	1.0	60
38	Hypoxic pulmonary hypertension in chronic lung diseases: novel vasoconstrictor pathways. Lancet Respiratory Medicine,the, 2016, 4, 225-236.	5.2	60
39	Beyond a single pathway: combination therapy in pulmonary arterial hypertension. European Respiratory Review, 2016, 25, 408-417.	3.0	53
40	Poor Outcomes Associated with Drainage of Pericardial Effusions in Patients with Pulmonary Arterial Hypertension. Southern Medical Journal, 2008, 101, 490-494.	0.3	52
41	Challenges in the diagnosis and treatment of pulmonary arterial hypertension. European Respiratory Review, 2012, 21, 313-320.	3.0	52
42	Combination Therapy and New Types of Agents for Pulmonary Arterial Hypertension. Clinics in Chest Medicine, 2007, 28, 169-185.	0.8	51
43	A role for the CXCL12 receptor, CXCR7, in the pathogenesis of human pulmonary vascular disease. European Respiratory Journal, 2012, 39, 1415-1424.	3.1	47
44	The need to move from 6-minute walk distance to outcome trials in pulmonary arterial hypertension. European Respiratory Review, 2013, 22, 487-494.	3.0	47
45	Perioperative management of patients with pulmonary hypertension undergoing non-cardiothoracic, non-obstetric surgery: a systematic review and expert consensus statement. British Journal of Anaesthesia, 2021, 126, 774-790.	1.5	45
46	Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study. European Journal of Heart Failure, 2019, 21, 352-359.	2.9	40
47	Risk assessment in pulmonary arterial hypertension: Insights from the GRIPHON study. Journal of Heart and Lung Transplantation, 2020, 39, 300-309.	0.3	39
48	Action of fenfluramine on voltage- gated K+ channels in human pulmonary-artery smooth-muscle cells. Lancet, The, 1998, 352, 290.	6.3	37
49	Pulmonary arterial hypertension: tailoring treatment to risk in the current era. European Respiratory Review, 2017, 26, 170095.	3.0	32
50	Mendelian randomisation and experimental medicine approaches to interleukin-6 as a drug target in pulmonary arterial hypertension. European Respiratory Journal, 2022, 59, 2002463.	3.1	31
51	Short-term Outcome and Predictors of Adverse Events following Pulmonary Thromboendarterectomy. World Journal of Surgery, 1998, 22, 1029-1033.	0.8	30
52	Elevated Plasma CXCL12Î± Is Associated with a Poorer Prognosis in Pulmonary Arterial Hypertension. PLoS ONE, 2015, 10, e0123709.	1.1	27
53	Increased Levels of Prostaglandin D2 Suggest Macrophage Activation in Patients With Primary Pulmonary Hypertension. Chest, 2001, 120, 1639-1644.	0.4	26
54	Results of an Expert Consensus Survey on the Treatment of Pulmonary Arterial Hypertension With Oral Prostacyclin Pathway Agents. Chest, 2020, 157, 955-965.	0.4	26

#	Article	IF	Citations
55	Right Heart and Pulmonary Vessels Structure and Function. Echocardiography, 2015, 32, S3-10.	0.3	25
56	Continuous Intravenous Epoprostenol Therapy for Pulmonary Hypertension in Gaucher's Disease. Chest, 1999, 116, 1127-1129.	0.4	23
57	Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry. Respiratory Medicine, 2021, 178, 106220.	1.3	23
58	The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the <scp>GRIPHON</scp> study. European Journal of Heart Failure, 2022, 24, 205-214.	2.9	22
59	Primary Pulmonary Hypertension Is Not Associated With Scleroderma-Like Changes in Nailfold Capillaries. Chest, 2001, 120, 796-800.	0.4	21
60	Relationship Between Time From Diagnosis and Morbidity/Mortality in Pulmonary Arterial Hypertension. Chest, 2021, 160, 277-286.	0.4	21
61	Percutaneous Atrial Septostomy with Modified Butterfly Stent and Intracardiac Echocardiographic Guidance in a Patient with Syncope and Refractory Pulmonary Arterial Hypertension. Heart Lung and Circulation, 2013, 22, 668-671.	0.2	20
62	Medical and Surgical Treatment Options for Pulmonary Hypertension. American Journal of the Medical Sciences, 1998, 315, 179-184.	0.4	19
63	Detection of High-Sensitivity Troponin in Outpatients With Stable Pulmonary Hypertension Identifies a Subgroup at Higher Risk of Adverse Outcomes. Journal of Cardiac Failure, 2014, 20, 31-37.	0.7	18
64	Nonâ€severe COVIDâ€19 is associated with endothelial damage and hypercoagulability despite pharmacological thromboprophylaxis. Journal of Thrombosis and Haemostasis, 2022, 20, 1008-1014.	1.9	18
65	Interferon beta related pulmonary arterial hypertension; an emerging worrying entity?. Multiple Sclerosis and Related Disorders, 2015, 4, 284-286.	0.9	16
66	Idiopathic pulmonary arterial hypertension and coâ€existing lung disease: is this a new phenotype?. Pulmonary Circulation, 2020, 10, 1-8.	0.8	16
67	Bosentan: A novel agent for the treatment of pulmonary arterial hypertension. International Journal of Clinical Practice, 2004, 58, 69-73.	0.8	15
68	Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study. Thrombosis Journal, 2018, 16, 9.	0.9	15
69	Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI 2) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) study. Journal of Heart and Lung Transplantation, 2018, 37, 401-408.	0.3	15
70	Anastomotic Pulmonary Hypertension After Lung Transplantation for Primary Pulmonary Hypertension. Chest, 1999, 116, 564-566.	0.4	13
71	Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry. Respiratory Medicine, 2021, 177, 106241.	1.3	13
72	Routine Hematological Parameters May Be Predictors of COVID-19 Severity. Frontiers in Medicine, 2021, 8, 682843.	1.2	13

#	Article	IF	Citations
73	Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension. Advances in Therapy, 2022, 39, 796-810.	1.3	12
74	Induction of Heme Oxygenase-1 with Hemoglobin Depresses Vasoreactivity in Rat Aorta. Journal of Vascular Research, 1999, 36, 114-119.	0.6	11
75	Platelets, extracellular vesicles and coagulation in pulmonary arterial hypertension. Pulmonary Circulation, 2021, 11, 1-9.	0.8	11
76	Management of pulmonary arterial hypertension. Current Opinion in Critical Care, 2013, 19, 44-50.	1.6	8
77	Pulmonary Vascular Endothelial Responses are Differentially Modulated After Cardiopulmonary Bypass. Journal of Cardiovascular Pharmacology, 1999, 34, 518-525.	0.8	8
78	Migraine with aura following atrial septostomy for pulmonary arterial hypertension. Nature Clinical Practice Cardiovascular Medicine, 2007, 4, 55-58.	3.3	6
79	Medical Treatment of Pulmonary Arterial Hypertension. Seminars in Respiratory and Critical Care Medicine, 2009, 30, 484-492.	0.8	6
80	ETNA VTE Europe: A contemporary snapshot of patients treated with edoxaban in clinical practice across eight European countries. European Journal of Internal Medicine, 2020, 82, 48-55.	1.0	5
81	ETNA-VTE Europe: Benefits and risks of venous thromboembolism treatment using edoxaban in the first 3Âmonths. Thrombosis Research, 2020, 196, 297-304.	0.8	5
82	Pulmonary hypertension and home-based (PHAHB) exercise intervention: protocol for a feasibility study. BMJ Open, 2021, 11, e045460.	0.8	5
83	Hepatopulmonary syndromes: treatment of liver transplantation candidates. Current Opinion in Organ Transplantation, 2002, 7, 107-113.	0.8	3
84	Relief of Chronic Neuropathic Pain through Endothelin Antagonism. American Journal of Medicine, 2010, 123, e7.	0.6	3
85	GuÃa de prÃ¡ctica clÃnica para el diagnÃ³stico y tratamiento de la hipertensiÃ³n pulmonar. Revista Espanola De Cardiologia (English Ed), 2009, 62, 1464.e1-1464.e58.	0.4	2
86	New drugs for pulmonary hypertension. , 2012, , 233-246.		2
87	â€œIt is the fear of exercise that stops meâ€•â€“ attitudes and dimensions influencing physical activity in pulmonary hypertension patients. Pulmonary Circulation, 2021, 11, 1-9.	0.8	2
88	Lung Transplantation for Pulmonary Hypertension. Seminars in Respiratory and Critical Care Medicine, 2001, 22, 533-540.	0.8	1
89	Pulmonary Vascular Disease. , 2013, , 603-625.		1
90	Characteristics of chronic thromboembolic pulmonary hypertension in Ireland. Pulmonary Circulation, 2021, 11, 1-6.	0.8	1

#	Article	IF	Citations
91	Progressive dyspnoea in a patient with idiopathic non-cirrhotic portal hypertension. Breathe, 2022, 18, 210168.	0.6	1
92	Incidence and outcomes of pulmonary hypertension in the Ireland. BMJ Open Respiratory Research, 2022, 9, e001272.	1.2	1
93	Chronic thromboembolic disease and necrotizing granulomatous vasculitis â€“ A case report. Respiratory Medicine CME, 2011, 4, 149-150.	0.1	0
94	Medical Treatment of Pulmonary Arterial Hypertension. Progress in Respiratory Research, 2012, , 237-245.	0.1	0
95	How the Right Heart Is Measuring Up in Pulmonary Hypertension. Chest, 2020, 157, 1-2.	0.4	0
96	An interesting case of progressive dyspnoea and diffuse mediastinal adenopathy in a 25-year-old man. Breathe, 2021, 17, 200289.	0.6	0
97	Diagnosis and Treatment of Pulmonary Arterial Hypertension. , 2014, , 1-33.		0
98	Diagnosis and Treatment of Pulmonary Arterial Hypertension. , 2015, , 4105-4133.		0
99	Pulmonary Vascular Disease. , 2005, , 661-680.		0